STOCK TITAN
  1. Home
  2. News
  3. TENX

Tenax Therapeutics Inc - TENX STOCK NEWS

Welcome to our dedicated news page for Tenax Therapeutics (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tenax Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tenax Therapeutics's position in the market.

News
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Rhea-AI Summary
Tenax Therapeutics, Inc. announces a scientific round-table discussion on the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role of levosimendan in treating this condition. The company will host a webcast to explore the ongoing Phase 3 LEVEL Study evaluating TNX-103 (oral levosimendan) for PH-HFpEF treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences clinical trial
-
News
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
Rhea-AI Summary
Tenax Therapeutics, Inc. (TENX) announces the enrollment of the first patient in the Phase 3 LEVEL trial for TNX-103 in treating Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The company secures global commercial rights for levosimendan, expands U.S. intellectual property, and hosts a KOL event. Recent corporate highlights include securing rights to oral and subcutaneous levosimendan, closing a public offering, and enrolling patients in the LEVEL study. Financially, Tenax reports $9.8 million in cash, raising $8.0 million in a public offering, with reduced R&D and administrative expenses resulting in a net loss of $7.7 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.56%
Tags
earnings clinical trial
-
News
Tenax Therapeutics to Present at the 36th Annual Roth Conference
Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) will participate in the 36th Annual Roth Conference to provide an update on the development of levosimendan, a cardiovascular and pulmonary disease treatment. CEO Chris Giordano will present on March 18, 2024, offering investors insights into the company's progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences
News
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Rhea-AI Summary
Tenax Therapeutics announces Dr. Sanjiv Shah's presentation on levosimendan for PH-HFpEF at THT 2024 conference in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.87%
Tags
none
-
News
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Rhea-AI Summary
Tenax Therapeutics, Inc. secures global rights to levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction, expanding territory from North America to worldwide. The agreement with Orion Corporation includes improved net sales royalty rates, modified milestone provisions, and exclusion of neurological indications from Tenax's right of first negotiation for new levosimendan applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
-
News
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
Rhea-AI Summary
Tenax Therapeutics, Inc. announced the pricing of a public offering of 1,600,000 shares of its common stock and warrants to purchase up to 3,200,000 shares at a purchase price of $5.65 per share. The offering is expected to close soon, with the proceeds intended for general corporate purposes and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.45%
Tags
offering
News
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Rhea-AI Summary
Tenax Therapeutics, Inc. has announced the enrollment of the first patient in the Phase 3 LEVEL Study, a trial for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The study will involve 152 patients and is expected to produce topline data by the second half of 2025. The company has highlighted the reduced costs and time for the registration of TNX-103 due to the FDA not requiring a long-term cardiovascular outcomes trial, and the extensive patent estate for levosimendan until at least 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.45%
Tags
clinical trial
-
News
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Rhea-AI Summary
Tenax Therapeutics, Inc. has been granted a patent providing U.S. intellectual property protection until December 2040 for the use of TNX-103, TNX-102, TNX-101, and active metabolites of levosimendan in the treatment of PH-HFpEF. The patent also covers the use of levosimendan in combination with various cardiovascular drugs for improving exercise performance in PH-HFpEF patients. The new patent broadens existing IP claims, including coverage of expanded dose ranges and drug combinations. The company aims to evaluate the clinical utility of levosimendan in other areas of cardiovascular disease, with a focus on the Phase 3 LEVEL study. This patent adds significant value to the company's IP portfolio and future drug development endeavors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.31%
Tags
none
-
News
Tenax Therapeutics Announces Reverse Stock Split
Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a 1-for-80 reverse stock split aimed at addressing Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding shares from 23,862,434 to approximately 292,281, with no change to authorized shares or par value per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.79%
Tags
none
News
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company’s PH-HFpEF Scientific Advisory Board. Dr. Butler, a renowned clinical trialist in cardiovascular medicine, will join the distinguished SAB overseeing the development of levosimendan. This follows the FDA clearance of Tenax’s planned Phase 3 investigation of oral levosimendan in PH-HFpEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
management
Stock TENX logo
Tenax Therapeutics Inc

Nasdaq:TENX

TENX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TENX Stock Data

7.36M
1.84M
0.36%
4.08%
2.5%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Morrisville

About TENX

tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.